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A B S T R A C TThe detection and molecular analysis of circulating tumour cells (CTCs) potentially provides a significant insight
to the characterisation of disease, stage of progression and therapeutic options for cancer patients. Following on
from the protocol by Warkiani et al. 2016, which describes a method of enriching CTCs from cancer patient blood
with inertial microfluidics, we describe a method to measure the CTC RNA expression in the enriched fraction
using droplet digital PCR and compare transcript detection with and without RNA pre-amplification.
 Inertial microfluidics combined with droplet digital PCR is advantageous as it allows for CTC enrichment and
subsequent RNA analysis from patient blood. This allows for patient tumour analysis with increased sensitivity
and precision compared to quantitative Real Time PCR and enables the direct quantification of nucleic acids
without the need for tumour biopsy.
 This method demonstrates an efficient approach providing important insights into the analysis of colorectal










cretype or expanded to larger panels.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/). Corresponding author at: Future Industries Institute and ARC Centre of Excellence in Convergent Bio-Nano Science and
chnology, University of South Australia, Mawson Lakes Campus, Mawson Lakes, South Australia, Australia.
 Corresponding author at: School of Biomedical Engineering, University of Technology Sydney, Sydney, Ultimo, NSW,
stralia.
E-mail addresses: marnie.winter@mymail.unisa.edu.au (M. Winter), Jean.cz@qq.com (Z. Cai), katharinaw1@gmx.net
. Winkler), kristen.georgiou@flinders.edu.au (K. Georgiou), dan.j.inglis@gmail.com (D. Inglis), tlavranos@bionomics.com.au




15-0161/© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://
ativecommons.org/licenses/by/4.0/).
M. Winter et al. / MethodsX 6 (2019) 1512–1520 1513A R T I C L E I N F O
Method name: Circulating tumour cells isolation and analysis with droplet digital PCR
Keywords: Circulating tumour cell, Droplet digital PCR, Colorectal cancer
Article history: Received 4 December 2018; Accepted 12 June 2019; Available online 17 June 2019Specifications Table
Subject Area: Biochemistry, Genetics and Molecular BiologyMore specific subject area: Digital Molecular Biology
Method name: Circulating tumour cells isolation and analysis with droplet digital PCRName and reference of
original method:Warkiani, Majid Ebrahimi, Bee Luan Khoo, Lidan Wu, Andy Kah Ping Tay, Ali Asgar S. Bhagat,
Jongyoon Han, and Chwee Teck Lim. "Ultra-fast, label-free isolation of circulating tumor
cells from blood using spiral microfluidics." Nature protocols11, no. 1 (2016): 134.Resource availability: n/aMethod details
Background
It has been well established that circulating tumour cells (CTCs) isolated from the blood of cancer
patients provide the potential for non-invasive prognostic and molecular insights [1–3]. Historically
CTC enumeration has been used as an independent prognostic indicator, however, enumeration alone
does not provide molecular information or therapeutic options for the patients’ disease. The
enrichment and detection of smaller numbers of CTCs leading to earlier identification of disease and
detection of relapse has allowed the approach to shift towards molecular characterisation of CTCs to
better guide patient treatment, provide better prognostics and monitor response to therapy [4]. There
has been significant research in developing technologies to enrich CTCs. These approaches often
include immuno-isolation which rely solely on the expression of epithelial markers. However, the
metastatic portion of cells are often in a state of epithelial to mesenchymal transition [5] meaning that
prognostically relevant CTCs may not express epithelial markers (in fact, mesenchymal cells are often
associated with poorer patient prognosis [6,7]). Therefore, an immuno-unbiased enrichment
approach based on the CTCs’ physical features may be preferable towards objective characterization of
the disease molecular phenotype. Inertial microfluidics provides an immuno-unbiased CTC
enrichment strategy which has previously been shown to yield an 80% recovery of cancer cell line
spiked in to healthy blood. Inertial microfluidics has been applied successfully in the enrichment of
CTCs in a number of cancer types including advanced stage metastatic breast and lung [8,9]. As well as
enabling the processing of relatively large volumes of blood after red blood cell (RBC) lysis (>7.5 mL) in
a few minutes, inertial microfluidics also allows for downstream analyses using various techniques
including immunofluorescence, cell culture, fluorescence in situ hybridisation (FISH), quantitative real
time – polymerase chain reaction (qRT-PCR) and even single cell analysis as previously outlined
[10,11]. As described by Warkiani and colleagues, inertial microfluidic devices work via inherent Dean
vortex flows present in curvilinear microchannels under continuous flow, and through inertial lift
forces. This results in smaller particles being trapped in the Dean vortices towards the outer channel
walls which are removed by the outer outlet, while the larger particles (CTCs) equilibrate near the
inner channel wall and are collected from the inner outlet [9].
Droplet digital PCR (ddPCR) is advantageous as it has been shown to have increased sensitivity and
precision over traditional qRT-PCR, providing direct quantification of nucleic acids from a wider range
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nucleic acid content with greatly increased sensitivity of detection [13]. DdPCR has been used for the
molecular detection and analyses of CTCs in a number of studies in combination with several
enrichment techniques (e.g. magnetic beads) [14–16]. Therefore, the combination of immuno-
unbiased size based high throughput CTC enrichment provided by inertial microfluidics and the
sensitivity of ddPCR is ideal for the molecular characterization of CTCs isolated from patients’ blood.
Following on from the published protocol by Warkiani et al. which describes a method of enriching
CTCs from patient blood with inertial microfluidics [17], we describe a method to measure the
expression of CTC RNA in the enriched fraction using ddPCR with and without RNA pre-amplification.
Initially, we used cancer cell lines spiked into healthy blood to validate and optimise ddPCR for the
specific panel of gene markers indicative of epithelial or tumour cells. After optimisation, the
technique of inertial microfluidic enrichment and ddPCR for the detection of the specific markers of
interest was performed on a small number of colorectal cancer patient samples. The presence of CTC
specific markers was confirmed in the samples, demonstrating the utility of this protocol.
CTC isolation
CTCs were isolated using a trapazoidal spiral inertial microfluidic device as previously described
[17]. The trapazoidal spiral inertial microfluidic device design and fabrication has previously been
described [9,17]. Moulds for chips were fabricated using standard micromilling at the South Australian
or New South Wales nodes of the Australian National Fabrication Facility with each being subjected to
a strict quality control protocol.a) 9 ml blood samples were collected (for both healthy persons and CRC patient blood) in a cell free
DNA BCT tube (218962; Streck, Nebraska, USA), stored at room temperature and processed within
24 h.b) Red blood cells were lysed using a commercial lysis buffer (gBioscience RBC Lysis buffer; 786–849)
with 35 ml of lysis buffer used per 9 ml of blood. Samples were placed on a gentle shaker for 15 min
at room temperature before centrifugation for 10 min at 500 g with a slow brake.c) Supernatant was removed from the cell pellet and the pellet resuspended in PBS (14190-144, Gibco
TM) (all pipette tips were pre-coated with 0.2% Poly(ethylene glycol)-block-poly(propylene glycol)-
block-poly)ethylene glycol)(Pluronic1F-108, Sigma-Aldrich; 542342). The pellet was resuspended
in 3 volume of PBS than initial blood volume (i.e. 9 ml blood in 27 ml PBS).d) Microfluidic device enrichment was performed as described in Warkiani et al. [17]. Briefly, the device
channels were coated with 1% bovine serum albumin and the resuspended pellet was injected (TYD01-
02, Leadfluid) through the slanted inertial microfluidic device at a constant rate of 1700 ml/min.e) The enriched fraction was collected and pelleted with centrifugation for 10 min at 500 g.
f) The supernatant was removed, the cell pellet resuspended in in 500 ml of RNA later and stored
at 80 C until analysis.
Note: Streck cell free DNA BCT tubes were used for this purpose as they contain a light preservative
which allows for storage and shipping of samples without significant cellular degradation [18].
RNA extractiona) The enriched sample (in RNA later) was centrifuged for 10 min at 3,500 g, and the RNAlater
removed.b) 100 ml of extraction buffer was added to the pellet as per manufacturer’s instructions (PicopureTM
RNA Isolation kit, Thermofisher, KIT0204) and was mixed well.
c) The sample and extraction buffer was incubated for 30 min at 42 C.
d) The Picopure column was activated by adding 250 ml of conditioning buffer for 5 min at room
temperature. The column was then centrifuged at for 1 min 16,200 g.
e) 100 ml of ethanol (from the Picopure kit) was added to the 100 ml of extraction buffer (RNA
mixture), the sample was mixed well, added to column and centrifuged for 2 min at 100 g.
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8000 g.g) 100 ml of washing buffer #2 from Picopure kit was added to column and centrifuged for 1 min at
8000 g. Next, 100 ml of washing buffer #2 was again added to column and centrifuged for 2 min at
16,000 g and then 1 min at 16,000 g.h) 11.5 ml of elution buffer was then added to column, incubated for 1 min and centrifuged for 1 min at
16,000 g.i) 1.5 ml of the 10x ezDNAse buffer, 1 ml of nuclease free water and 1.5 ml of the ezDNAse were added
to 11 ml of RNA as per the manufacturer’s instructions (11766051, Thermofisher). Sample was
incubated for 2 min at 37 C and then placed at 4 C.j) RNA quantity was measured using the Qubit RNA HS Assay Kit as per the manufacturer’s
instructions (Q32852, Thermofisher). New standards were prepared before each set of readings
(10 ml of standard and 190 ml of buffer). 3 ml of ezDNAse treated RNA sample was added to 1 ml of
dye and 196 ml of buffer and the concentration was read using a Qubit 2.0 fluorometer
(Thermofisher).
Note: The presence of genomic contamination was monitored when analysing extracted RNA
samples. For our set-up it was found with the Picropure RNA isolation kit alone that occasionally there
was significant genomic contamination. Therefore, various methods (ezDNAse, Turbo DNA-freeTM,
Purelink RNA mini kit, Thermofisher) for additional DNAse treatment were investigated. DNAse
treatment time was also investigated and determined that 2 min was adequate to prevent genomic
contamination. ezDNAse (Thermofisher) was selected as the best method to eliminate the issue of
genomic contamination.
cDNA synthesisa) As per manufacturer’s instructions, per sample 4 ml of 5x iScript advanced reaction mix, 1 ml of
iScript reverse transcriptase (1725038, BioRad) and 4 ml of nuclease free water was added to 11 ml
of ezDNAse treated RNA.b) Sample was placed in thermocycler and was run as per the following protocol: 20 min 46 C, 1 min
95 C and held at 4 C.
Pre-amplification
Due to the low amount of CTCs in enriched samples, we investigated the use of pre-amplification to
increase the detectable amount of target RNAs. Pre-amplification was performed with Taqman pre-
amplification master-mix as per manufacturer’s instructions (Thermofisher Scientific). For each blood
sample pre-amplification was performed on 10 ml of cDNA. In this instance, we amplified using probes
from the selected panel of CRC markers: KRT-19, CEACAM5, AGR2, FDZ7 and LGR5.
Briefly for each sample, 25 ml of 20 Taqman preamp master mix (4391128, Thermofisher) was
added to 12.5 ml of probe mix (1 ml of each probe LGR5, CEACAM5, KRT19 (Keratin 19), AGR2, FDZ7 in
95 ml Tris-EDTA (TE) buffer (AM9849, Thermofisher)) and then 2 ml of nuclease free water and 10 ml of
cDNA was added. The sample was then placed in the thermocycler and run as per the following
protocol (10 min 95 C then 15 s 95c and 4 min 60 C repeated 9 and held at 4 C). Pre-amplified
solution was again diluted with dH2O 1:5 for running with the ddPCR.
To investigate pre-amplification utility we firstly used 10 or 50 of the ATCC1 CCL-229TM LoVo cells
(colon, derived from left supraclavicular region metastasis) either in the presence or absence of WBCs
to simulate normal enriched conditions. To quantitate efficiency, we used the Qubit 2.0 fluorometer
for measurement of high sensitivity (HS) RNA (Q32852) and single stranded DNA (ssDNA; Q10212).
However, the ssDNA measurement is only relevant if the sample does not have background WBC
contamination (as the pre-amplification will only amplify targets spiked into the mix). Therefore, we
determined the best way to measure efficiency was to use ddPCR. We directly compared the same
sample before and after amplification and it was found that 20–100 more positive droplets were
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pre-amplification, in order to obtain a quantitative measurement (without pre-amplification) and a
qualitative measurement (with pre-amplification) with multiple markers and a greater number of
replicates (which is afforded by preamplification and is perhaps the biggest advantage).
Droplet digital PCR
For each probe, the optimum annealing/extension temperature was investigated with a
temperature gradient. It was found that 1 min for 60 C was optimum for all probes in the expected
temperature range for the assay. The optimum concentration for each probe was also investigated and
it was found that 1.1 ml of each probe per reaction gave maximal results.
Initially, probes were run individually with cDNA from either 10 or 10,000 ATCC1 HT-29 (HTB-
38TMcolorectal adenocarcinoma derived, epithelial cells) cells (or LoVo cells) and expression was
quantified. Two probes were then used together per analysis sample enabling the simultaneous
detection on the FAM and HEX channels, either KRT19 and CEACAM5 or LGR5 and AGR2/FDZ7. The
copies/ml of the target was compared alone and in combination. It was determined that the use of two




bloFor each well, 1.1 ml of probe (2 probes per well, CEACAM5 FAM and KRT19 HEX or AGR2 FAM, LGR5
HEX), 11 ml of ddPCR supermix (1863024, Bio Rad), 4 ml nuclease free water, 4.8 ml cDNA for a final
volume of 22 ml was added and mixed well. The plate was sealed with Biorad Aluminium plate seal
(#1814040) and the plate was centrifuged for 30 s at room temperature.2 The plate was placed in the QX200TM AutoDGTM droplet generation robot (Bio Rad) and set up as per
manufacturer’s instructions.3 After droplet generation, the plate was placed into thermocycler (Eppendorf deep well
thermocycler) as per instructions for ddPCR Probe assay (PrimePCRTM ddPCRTM Gene Expression
Probe Assays; Bio Rad). i.e. enzyme activation 95 C for 10 min, denaturation for 15 s 94 C,
annealing/extension for 1 min 60 C (denaturation/extension repeated 39 cycles), enzyme
deactivation 98 C and hold at 4 C with a ramp rate of 2 C/sec.4 The plate was then placed in QX200 Droplet digital PCR system and run as an absolute
quantification experiment as per manufacturer’s instructions.5 Analysis was then performed in QuantaLife (Bio Rad)..1. Column graph representing total positive droplet numbers for KRT19 (blue) and and CEACAM5 (green) for 10 LoVo cells in
0,000 WBC for samples without pre-amplification (designated cDNA) and those with pre-amplification (PA) and indicated
utions. For all subsequent experiments pre-amplified samples were diluted 1:5 as per the manufacturer’s instructions, as well
 providing a larger volume for analysis dilution may potentially prevent precipitation which could in turn cause channel
ckage during droplet generation and reduce the number of droplets.
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expected expression levels i.e. high expressing KRT19 was runwith HEX while CEACAM5 was runwith FAM.
Note: Multiplexing with more than 2 probes involves mixing different amounts of FAM and HEX
probes in various proportions to enable detection. The use of 5 probe multiplexing was investigated,
however, proved problematic and unreliable for this specific application (due to the extreme rarity of
markers) and it was ultimately decided to limit to 2 probes per reaction.
Note: It is understood that in ddPCR false positive droplets will occur in no-template control runs
and for negative samples (blood samples prepared in the same way as patient samples but are from a
healthy control, constitutes~100,000 WBC). It is therefore, important to determine false positive rates
for each probe and no template controls are continually run to determine the presence of reagent
contamination and other errors. False positive rates assume all sources, droplets, detection, assays and
contamination. False positive rate is calculated as number of events per well and used to calculate the
limit of detection. False positive rate is different for each probe and must be calculated independently.
We initially investigated FDZ7 as a marker of CTCs, however, it was found that the expression of this
marker was too high in WBCs to detect CTC expression, as has been previously described [19].
Therefore, it was decided that FDZ7 would not be used for further analysis.
Note: We observed that pre-amplification significantly increases the number of false positive
events (except for CEACAM5 which remained low) and therefore, while there is increase in the
number of positive droplets, there is also a higher threshold over which a well can be considered truly
positive (Table 1). Therefore, the number of false positives was investigated with and without pre-
amplification. For both cDNA and pre-amplified cDNA false positivity rate was calculated. To calculate





cDNAFalse positve rate ¼ Total number of  positive droplets
Number of  wellsBased on the false positive rate, the number of positive droplets required per well to be a
considered a true positive (with 95% confidence was calculated based on data table available from Bio-
Rad (California, USA). For CEACAM5 which has a false positive rate of 0.6%, the threshold to assess a
positive well was 3 positive droplets for 95% certainty that the result is a true positive. For
KRT19 which has a 7.4% false positive rate, the threshold to assess a positive well is 22 positive droplets
for 95% certainty that the result is a true positive. For LGR5 which has a 7.4% false positive rate the
threshold to assess a positive well is 22 positive droplets for 95% certainty that the result is a true
positive. For AGR2 which has a 32.1% false positive rate, the threshold to assess a positive well is
96 droplets for 95% certainty. This number of droplets is unrealistic and it is likely that these samples
do not represent a true negative, therefore, similar to FDZ7, AGR2 is not a feasible marker to aid in the
detection of CRC CTCs in this instance, although its utility has however, previously been demonstrated
as a marker for prostate cancer CTCs [20].
Method validation
Detection sensitivity
Using a dilution series, as few as 12 LoVo cells could be detected in 1 well using the CEACAM5
probe (Fig. 2). As low as 3 LoVo cells per well with the KRT19 probe could be detected attributed toositive rates (FPR) for the four markers investigated (CEAMCAM5, KRT19, LGR5 and AGR2) for both pre-amplified and
lified cDNA.
CEACAM5 KRT19 LGR5 AGR2
FPR Positive Droplets FPR Positive Droplets FPR Positive Droplets FPR Positive Droplets
mplified 0.595 3 7.420 22 7.615 22 32.075 96
 0.045 2 0.200 3 – – – –
Fig. 2. Standard curves to clarify the relationship between number of cells (amount of RNA) and the copy number per mL for
both CEACAM5 and KRT19 calculated based on cDNA dilutions from LoVo cDNA.
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number of CTCs detectable in a patient sample will be higher as KRT19 expression is expected to be
lower than in cancer cell lines.
Spiking experiments and patient samples
Experiments spiking both HT-29 and LoVo cells into equivalent numbers of WBC background that is
typically obtained following inertial microfluidic enrichment were first performed. It was found that
the detection sensitivity was reduced with the presence of WBCs. Moreover, the presence of WBCs
considerably increased the number of false positives (hence increasing the number of positive
droplets needed to be considered a true positive) and decreased the limit of detection. Low numbers of
LoVo cells (20 cells) could be detected within a background WBC population from 9 ml of enriched
blood.
Blood samples from CRC patients were processed as per the described protocol and expression of
CTC markers was measured (Supplementary Information Table 1). The presence of CTC specific
markers (hence CTCs) was confirmed in some of the patient samples in 1 or multiple samples from the
same patient. This study has shown that mRNA expression of genes specific to epithelial or tumor cells
can be detected in colorectal cancer patient samples.
Summary
This article has described a method to assess mRNA expression of genes specific to epithelial or
tumour cells with ddPCR after inertial microfluidic enrichment of CTCs from patient blood
samples. It is shown that this method can be used to detect colorectal cancer patient CTCs. The
detection of potential CTCs with ddPCR is made possible through the initial size based enrichment
with the inertial microfluidic device as originally described by Warkiani et al. [17].Table 2
Number of positive droplets detected with various LoVo cell numbers in presence of WBC background (100,000) with or without
pre-amplification (PA).
KRT19 LGR5 CEACAM5
20 LoVo cells in WBC 0  0 0  0 0  0
20 LoVo cells in WBC (PA) 25.57  5.10 33.25  6.50 0  0
50 LoVo in WBC 21  4.55 33  5.00 8.33  3.68
50 LoVo in WBC (PA) 274.25  3.90 298.50  2.50 165.75  7.26
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